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Abstract Acute leukemias have a huge morphological, cytogenetic and molecular heterogene-
ity and genetic polymorphisms associated with susceptibility. Every leukemia presents causal
factors associated with the development of the disease. Particularly, when three factors are
present, they result in the development of acute leukemia. These phenomena are susceptibility,
environmental exposure and a period that, for this model, has been called the period of vul-
nerability. This framework shows how the concepts of molecular epidemiology have established
a reference from which it is more feasible to identify the environmental factors associated
with the development of leukemia in children. Subsequently, the arguments show that only sus-
ceptible children are likely to develop leukemia once exposed to an environmental factor. For
additional exposure, if the child is not susceptible to leukemia, the disease does not develop. In
addition, this exposure should occur during a time window when hematopoietic cells and their
environment are more vulnerable to such interaction, causing the development of leukemia.
This model seeks to predict the time when the leukemia develops and attempts to give a context
in which the causality of childhood leukemia should be studied. This information can inﬂuence
and reduce the risk of a child developing leukemia.
© 2016 Hospital Infantil de México Federico Gómez. Published by Masson Doyma México S.A.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).E-mail address: juan.mejiaa@imss.gob.mx
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Epidemiología  molecular  de  la  leucemia  aguda  en  nin˜os.  Modelo  causal  en  el  que
intervienen  tres  factores:  susceptibilidad,  exposición  ambiental  y  periodo  de
vulnerabilidad
Resumen  La  leucemia  aguda  representa  una  enfermedad  con  una  enorme  heterogeneidad
morfológica, citogenética,  molecular  y  polimorﬁsmos  genéticos  asociados  con  la  susceptibil-
idad.  Presenta  factores  causales  asociados  con  el  desarrollo  de  la  misma.  Particularmente,
cuando tres  fenómenos  se  conjuntan,  traen  como  resultado  el  desarrollo  de  la  leucemia  aguda.
Estos  fenómenos  son  la  susceptibilidad,  la  exposición  ambiental  y  un  periodo  que,  para  este
modelo,  ha  sido  denominado  el  periodo  de  vulnerabilidad.  El  presente  marco  teórico  muestra
cómo  los  conceptos  de  la  epidemiología  molecular  han  permitido  establecer  una  referencia  a
partir  de  la  cual  es  más  factible  identiﬁcar  los  factores  ambientales  relacionados  con  el  desar-
rollo  de  la  leucemia  en  nin˜os.  Posteriormente  se  muestran  los  argumentos  para  predecir  que
solo  los  nin˜os  susceptibles  probablemente  desarrollarán  leucemia  una  vez  que  se  exponen  a  un
factor  ambiental.  Por  lo  que,  por  más  exposición,  si  el  nin˜o  no  es  susceptible  a  la  leucemia,  no
la  desarrollará.  Además,  esta  exposición  debe  ocurrir  durante  una  ventana  de  tiempo  durante  el
cual  las  células  hematopoyéticas  y  su  entorno  son  más  vulnerables,  para  que  dicha  interacción
provoque  el  desarrollo  de  leucemia.  Este  modelo  pretende  predecir  el  momento  en  el  cual  se
desarrollará  la  leucemia  y  trata  de  dar  un  contexto  en  el  que  la  causalidad  de  la  leucemia  en
nin˜os  deberá  ser  estudiada.  A  través  de  esto  se  podrá  inﬂuir  y  disminuir  el  riesgo  de  que  un  nin˜o
desarrolle  leucemia.
© 2016  Hospital  Infantil  de  México  Federico  Gómez.  Publicado  por  Masson  Doyma  México  S.A.
Este  es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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t. Introduction
his  model  aims  to  lay  the  groundwork  to  identify  factors
ssociated with  the  development  of  acute  leukemia  (AL)  in
hildren. First,  the  concepts  of  molecular  epidemiology  are
xplained, which  are  those  that  give  rise  to  this  theoreti-
al model.  Subsequently,  the  components  of  the  model  are
escribed and,  ﬁnally,  a  description  of  the  same  is  done.
. Molecular epidemiology
or  Shulte,  molecular  epidemiology  emerges  as  an  evolu-
ionary state  of  the  epidemiology  in  which  it  will  not  only
e important  to  identify  the  risk  factors  of  the  diseases.  The
echanisms that  lead  to  their  development  can  be  identiﬁed
hrough molecular  epidemiology.  From  this  point  of  view,
t will  result  in  the  emergence  of  new  theories  and,  with
t, the  maneuvers  for  disease  prevention  in  the  population
an more  accurately  be  directed.1 The  Shulte  concept  has
roved some  reactions:  some  in  favor,2--15 others  against16--18
nd  others,  although  they  do  not  discard  molecular  epidemi-
logy as  a  new  discipline  question  it  and  expect  its  prompt
trengthening.19--23 Table  1  shows  the  most  common  deﬁni-
ions of  molecular  epidemiology.14
What  allows  us  to  speak  of  a  new  discipline  are  not
nly the  techniques  or  tools  applied  in  the  epidemiol-
gy, but  the  concepts  that  this  brings.  These  concepts
re the  internal  dose,  the  effective  biological  dose,  early
iological effects  and  the  altered  function  and  structure,
oncepts that  are  made  operational  though  the  different
iomarkers.1 In  this  sense,  the  biomarkers  can  be  divided
nto biomarkers  of  exposure,  effect  and  susceptibility.1
b
e
ixposure  biomarkers  are  those  of  internal  dose,  biologi-
ally effective  dose  and  target  tissue  dose.  Susceptibility
iomarkers include  polymorphisms  in  genes  involved  in  the
etabolism of  carcinogens,  in  DNA  repair  and  in  the  control
f the  cellular  cycle.  Biomarkers  of  effect  evaluate  the  early
enetic alterations  and  the  modulation  of  the  nutritional  and
mmunological state  that  lead  to  tumorigenesis.4
Molecular  epidemiology  has  been  proposed  as  an  evolv-
ng state  of  the  classic  epidemiology,  which  for  some  only
epresents the  incorporation  of  new  techniques,  the  molec-
lar techniques,  in  epidemiological  designs,16,20 whereas  for
thers it  represents  the  best  way  to  explain  the  mecha-
isms related  with  the  health-disease  processes  in  human
opulations.1,4 This  provides  the  answer  to  the  problem  of
pidemiology that,  on  establishing  an  association  between
n environmental  factor  and  disease,  leaves  a  ‘‘black  box’’;
.e., that  cannot  clarify  the  mechanisms  by  which  this  factor
auses the  disease.1 In  such  a  case,  the  molecular  epidemi-
logy would  contribute  to  the  solution  for  this  black  box.2,24
However,  molecular  epidemiology  does  not  only  arise  as
n incorporation  of  new  molecular  techniques,  as  Shulte
imself proposes.  It  arises  from  the  identiﬁcation  of  individ-
als who,  despite  being  exposed  to  the  same  risk  factors,  do
ot present  the  same  response,  whether  it  is  because  they
o not  receive  the  same  dosage  (internal  dose,  effective
iological dose)  or  because  they  respond  metabolically  in  a
ifferent manner  to  the  substance  (susceptibility  biomark-
rs). It  also  arises  from  the  concern  of  identifying  in  a
imely manner  the  damage  caused  by  a  toxic  agent  (effect
iomarkers). This  leads  to  the  development  of  molecular
pidemiology.4,7,14
It  is  then  clear  that  in  any  epidemiological  investigation
t is  possible  to  apply  molecular  epidemiology,  although  not
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Table  1  Evolution  of  the  molecular  epidemiology  deﬁnition.
Author  (s)  Year  Deﬁnition
Higginson  J 1977 ‘‘The  application  of  sophisticated  techniques  to  the  epidemiologic
study  of  biologic  material’’
Schulte  PA  1993  ‘‘Molecular  epidemiology  is  the  use  of  biologic  markers  or  biologic
measurements  in  epidemiologic  research’’
Tompkins LS  1994  ‘‘The  application  of  molecular  biology  to  the  study  of  infectious
disease  epidemiology’’
McMichael  AJ  1994  ‘‘Using  molecular  biomarkers  in  epidemiology’’
Groopman JD,  Kensler  TW,
Links JM.
1995  ‘‘Molecular  epidemiologic  research  involves  the  identiﬁcation  of
relations between  previous  exposure  to  some  putative  causative
agent and  subsequent  biological  effects  in  a  cluster  of  individuals  in
populations’’
Hall A  1996  ‘‘The  analysis  of  nucleic  acids  and  proteins  in  the  study  of  health  and
disease determinants  in  human  populations’’
Shpilberg O,  Dorman  JS,
Ferrell RE,  et  al.
1997 ‘‘Molecular  epidemiology  uses  molecular  techniques  to  deﬁne
disease and  its  pre-clinical  states,  to  quantify  exposure  and  its  early
biological effect,  and  to  identify  the  presence  of  susceptibility
genes’’
Levin  BR,  Lipsitch  M,
Bonhoeffer S.
1999 ‘‘The  practical  goals  of  molecular  epidemiology  are  to  identify  the
microparasites  responsible  for  infectious  diseases  and  determine
their physical  sources,  their  biological  relationships,  and  their  route
of transmission  and  those  of  the  genes  responsible  for  their
virulence,  vaccine-relevant  antigens  and  drug  resistance’’
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tAdapted from Foxman and Riley (2001) (reference 14).
necessarily.  The  principal  level  of  analysis  of  epidemiology
is population  level,  and  its  principal  objective,  as  part  of
public health,  is  prevention.18 Epidemiology  achieved  the
biggest advance  with  regard  to  cancer  and  cardiovascular
disease prevention  by  establishing  a  relationship  between
these diseases  with  tobacco  consumption  without  the  need
for molecular  epidemiology.25--28 It  is  not  the  fact  that  most
diseases in  humans  are  multicausal,  which  determines  the
emergence of  molecular  epidemiology,1 or  fallen  into  an
environmental reductionism  in  search  of  an  only  risk  fac-
tor for  identifying  causality  of  a  disease.2 Identiﬁcation  of
smoking as  a  sole  environmental  factor  associated  with  lung
cancer or  with  coronary  disease  offered  an  important  answer
to the  causality  and  prevention  of  these  diseases.27--29 Almost
80% of  the  different  types  of  lung  cancer  and  50%  of  ischemic
heart diseases  are  caused  by  tobacco.25,30,31
Molecular  epidemiology  emerges  as  an  alternative  when
it is  not  possible  to  identify  environmental  factors  of  disease
in the  population  and  when  it  has  been  demonstrated  that
a substance  is  potentially  harmful  at  the  individual  or  basic
levels.32 This  could  be  the  result  of  errors  in  measurement
of the  exposure  or  it  may  be  that  some  individuals  have  dif-
ferent responses  to  a  particular  substance.4,32 In  those  cases
there is  no  other  alternative  than  molecular  epidemiology.1,3
To  use  molecular  techniques  in  associations  shown  by  epi-
demiology results  in  the  accumulation  of  further  evidences
of the  epidemiological  association.1,28 However,  it  is  also
likely that  there  is  a  fetishism  of  the  indiscriminate  use
of the  technology  that  may  lead  to  the  thinking  that  with
the advanced  technology  one  may  come  to  a  greater  under-
standing of  the  biological  phenomenon,  which  could  be
an error.33 You  can  continue  to  demonstrate  that  tobacco
causes lung  cancer,  and  pass  all  levels  of  measurement,
a
o
m
eove  from  the  population  level  to  the  individual  level,  and
rom there  to  the  molecular;34 however,  this  is  not  what
llows explaining  the  health-disease  process.34 On  the  con-
rary, many  times  this  only  generates  hierarchies  between
isciplines and  a  false  idea  of  the  greater  strength  of  the
nding. It  is  believed  that  it  is  explained  further  when  all
hat is  achieved  is  a description  at  a  lower  level  of  measure-
ent in  a  more  reductionist  vision  of  the  phenomenon.35
inding  traces  of  derivatives  of  tobacco  in  malignant  lung
issue is  not  evidence  of  the  association  between  tobacco
nd lung  cancer,  but  a  retrograde  vision  of  single  cause  the-
ry of  Koch’s  postulates,  which  are  unable  to  explain  the
ealth/disease process  in  human  populations.36
Epidemiology  has  a predominant  value  in  public  health
hat does  not  depend  on  the  techniques  used  to  substanti-
te its  ﬁndings.  Neither  the  causality  of  diseases  nor  their
revention depends  on  the  techniques  used.18 Snow,  Doll  and
ill did  not  use  great  techniques  to  prevent  the  diseases  they
tudied.27,37 Causality  depends  more  on  the  value  judgments
han on  the  techniques  used.38,39
Molecular  epidemiology  is  a  branch  of  epidemiology  and,
or some  in  particular,  a  branch  of  clinical  epidemiology.1
t  is  not  an  evolving  state  where  what  evolves  is  better  or
tronger than  what  it  leaves  behind.1,20 It  is  a  branch  that
ill develop  in  parallel  to  the  trunk;  public  health  devel-
ps and  incorporates  new  concepts  and  techniques  to  its
uties.18,21
The  advantage  of  molecular  epidemiology  is  then  related
o the  dosages  that  are  really  absorbed  (internal  dose)
nd to  the  dosages  capable  of  producing  an  effect  on  the
rganism (effective  biological  dose),  events  that  are  not
easured and  many  times  not  even  considered  by  classic
pidemiology. On  the  other  hand  is  the  evaluation  of  the
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nteraction  between  environmental  exposure  and  genetic
olymorphism, which  intervenes  in  the  metabolism  of  tox-
ns. Finally,  molecular  epidemiology  is  able  to  identify  the
nitial damage  caused  to  the  body  by  a  substance  or  agent;
herefore, it  is  feasible  to  reach  the  early  identiﬁcation  of
he disease.1,4,32 Without  molecular  epidemiology  it  would
ot be  possible  to  achieve  all  of  this.32
One  of  the  most  promising  ﬁelds  within  molecular
pidemiology  is  to  identify  the  interaction  between  envi-
onmental exposures  and  susceptibility  of  the  individual
s a  way  of  identifying  those  persons  truly  at  risk7 and,
n the  other  hand,  to  identify  factors  that  had  not  been
etected as  carcinogenic  in  population  studies.4,11 The  ﬁnd-
ng of  associations  between  an  exposure  and  disease  could
e more  noticeable  in  a  particular  genetic  polymorphism28
r  in  individuals  susceptible  to  the  disease.7 The  study  of
he population  at  greater  risk  of  suffering  from  a  disease
ould be  a  good  model  to  predict  what  would  happen  to
he general  population.1,4 At  the  least,  factors  that  could
ncrease the  risk  of  suffering  from  a  disease  will  be  able  to
e identiﬁed.4
Finally,  the  limitations  of  molecular  epidemiology  should
e made  clear.21 It  has  been  long  known  that  the  dose
oes not  necessarily  reﬂect  the  degree  of  involvement  in
n individual,  especially  when  we  are  dealing  with  infec-
ious diseases.36 It  is  also  important  to  point  out  that  the
ffective biological  dose  is  not  necessarily  an  indicator  that
he disease  will  progress,  given  that  extensive  damage  to
he cells  is  reversible.40 Not  even  the  declared  states  of  dis-
ases are  a  guarantee  that  there  may  not  be  an  involution
f the  disease.41 Doubt  then  arises  as  to  whether  it  would
lways be  advantageous  to  carry  out  an  early  diagnosis  given
hat in  some  cases  there  is  the  possibility  of  an  involution  of
he phenomenon.40,41 Another  major  problem  of  early  diag-
osis is  that  there  is  not  always  the  possibility  of  providing
ppropriate treatment  to  the  patient.42 It  should  also  be
entioned that  the  search  for  associations  between  expo-
ure to  carcinogens  and  genetic  polymorphisms  of  the  genes
hat intervene  in  the  metabolism  of  the  carcinogens  have
ffered contradictory  information  to  the  point  that  it  would
ppear that  this  is  not  the  path  that  explains  why  some  indi-
iduals develop  the  disease  and  others  do  not.43,44 Finally,
dentifying the  population  at  risk  is  not  always  advantageous
or the  prevention  of  disease42 because  factors  that  cause
he population  at  risk  to  develop  the  disease  are  not  yet
nown. On  the  contrary,  the  person  can  develop  a  degree
f anxiety  by  knowing  that  he/she  is  a  carrier  of  a  gene
hat can  increase  risk  of  suffering  from  a  disease,  yet  can-
ot be  counseled  as  to  what  exposures  should  be  avoided.18
nother  aspect  that  should  not  be  forgotten  is  that  using  bio-
ogical  material  for  diagnosis,  such  as  the  search  for  related
enes, causes  a  decrease  in  the  participation  of  the  pop-
lation or  the  power  to  capture  the  eligible  population,
hich itself  can  produce  the  presence  of  selection  bias.21,23
ne  cannot  then  leave  aside  that  molecular  epidemiology
aces the  same  problems  as  classic  epidemiology  and  that
he use  of  molecular  techniques  does  not  guarantee  that
he best  markers  are  being  used  for  the  measurement  of  the
xposure.21 It  should  be  kept  in  mind  that  not  all  biomarkers
ave been  validated.21,22 Use  of  the  technology  does  not  pre-
ent the  presence  of  selection  bias21,23 nor  does  it  guarantee
hat the  bias  of  confusion  can  be  eliminated.21
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Despite  its  limitations,  molecular  epidemiology  is  an
ccepted discipline  that  permits  the  identiﬁcation  of  why
ertain environmental  factors  in  some  populations  produce
isease and  others  do  not.24 Molecular  epidemiology  is  also
 good  example  of  interdisciplinary  research.1,4 There  are
wo types  of  interdisciplinary  research:  that  where  two  or
ore disciplines  unite  their  techniques  to  answer  the  same
esearch question  and  another  when  two  or  more  disciplines
erge their  concepts  to  answer  a  research  question.  The  lat-
er is  also  known  as  trans-discipline.45 Further  examples  of
olecular epidemiology  are  where  the  only  result  that  has
ccurred is  an  exchange  of  techniques  between  molecular
iology and  epidemiology.16,21,46 What  can  be  more  difﬁ-
ult is  to  reach  a  trans-discipline  where  the  disease  can
e explained  from  the  molecular  biology  and  epidemiology
oint of  view.  Whereas  for  one  discipline  the  most  important
hing is  what  occurs  in  the  population,  for  the  other  the  most
mportant  is  what  occurs  in  the  molecules.  Each  discipline
as different  ways  of  interpreting  reality  given  that  there
re different  concepts.21 However,  despite  there  being  only
ne intersection  currently  at  the  technical  level,  it  is  to  be
oped and  expected  that  a  mixture  of  concepts  exists  that
llow for  the  health/disease  process  to  be  explained  from
he molecular  level  up  to  the  population  level.21,22,46--48 An
xample of  this  is  the  model  that  attempts  to  explain  where
here is  an  intersection,  from  the  molecular  environment,
n the  development  of  leukemia  in  children.49
. Acute leukemia as result of the interaction
f different phenomena
.1.  Exposure
hen  mentioning  exposure  as  a  phenomenon,  it  should
e pointed  out  that  there  are  evidences  that  the  expo-
ures cause  AL  in  children.  However,  one  cannot  speak
f a  single  exposure  as  there  are  different  types.  The
ost consistent  in  the  development  of  AL  is  in  utero
xposure to  radiation.50 Occupational  exposures  follow  in
onsistency,51--54 especially  those  that  have  to  do  with  the
se of  petroleum  derivatives.54 However,  there  are  other
ypes of  exposures,  such  as  biological.  Such  is  the  case  of  the
nfectious agents,55,56 chemical  exposures  such  as  food  con-
aminated with  pesticides57,58 or  the  use  of  medications  such
s chloramphenicol.59 One  aspect  that  should  be  stressed
s that  very  few  cases  of  AL  can  be  explained  by  currently
nown exposure  factors  or  by  one  alone.49
Although  some  risk  factors  for  developing  AL  may  be  high,
n the  case  of  paternal  occupation  the  odds  ratio  can  vary
rom 2-5.51 In  fact,  few  cases  can  be  found  associated  with
ach factor  in  particular.54 What  could  the  child  have  been
xposed to  in  order  to  develop  AL?  It  could  have  been  x-
ay exposure  during  pregnancy,  an  infectious  agent  during
he ﬁrst  2 to  3  years  of  life,  a  toxic  agent  in  the  food  or
nvironment, electromagnetic  ﬁelds,  different  agents  in  the
ork environment  of  the  father  or  mother,  etc.49. Speciﬁcity
f the  exposure  may  not  be  so  important  because  factors
nvolved with  the  development  of  AL  may  be  associated  with
ther diseases.  For  example,  x-rays  are  associated  with  thy-
oid and  other  types  of  cancer;60 tobacco  consumption  by
he parents  and  exposure  to  hydrocarbons  are  associated
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with  lymphomas;61,62 and  electromagnetic  ﬁelds  and  resid-
ing close  to  areas  with  high-density  trafﬁc  with  tumors  of
the central  nervous  system.63 Perhaps  some  exposure  may  be
speciﬁc for  AL,  such  as  the  case  of  the  human  T-lymphotropic
virus type  1  (HTLV1)  virus  in  T-cells  AL;56,64 however,  this  is
not the  rule.  That  speciﬁcity  may  perhaps  have  more  to  do
with the  child’s  susceptibility  and  with  the  time  in  which  the
exposure takes  place.  This  could  also  explain  why  in  many
children who  have  been  exposed  to  the  same  factor,  only
some develop  the  disease.
3.2.  Susceptibility
The  most  common  susceptibility  factor  linked  to  the  devel-
opment of  AL  is  Down’s  syndrome.  Other  syndromes  are
associated with  a  high  risk  of  developing  AL  such  as  Li-
Fraumeni syndrome,65,66 Bloom  syndrome,  Fanconi  anemia,
Blackfan-Diamond syndrome  and  Schwachman-Diamond
syndrome,  among  others.65 However,  these  conditions  rep-
resent a  small  percentage  of  the  total  number  of  cases
with AL.65 In  utero  exposure  to  x-rays  and  Down’s  syndrome
represent only  10%  of  the  AL  cases.50 Current  molecular
techniques have  allowed  for  identiﬁcation  of  an  enormous
quantity of  molecular  variations  that  predispose  the  devel-
opment of  AL,  although  it  has  not  been  possible  to  arrive  at
a speciﬁc  treatment  in  all  cases.67
Another  factor  that  also  increases  susceptibility  is  the
human leukocyte  antigen  complex  (HLA;  also  known  as
major histocompatibility  complex  or  MHC  in  mice).  It  is
known that  the  association  between  an  HLA  allele  and
an oncogenic  factor  could  trigger  the  development  of
leukemia.68,69 An  exaggerated  response  may  exist  to  a
common infection  and  this  response  may  be  regulated  by
the HLA  system.69 In  addition,  depending  on  a  speciﬁc  HLA
allele, some  viruses  may  not  be  recognized  as  foreign  by  the
organism and  circumvent  immunological  defense  barriers
against the  cancer.69,70 This  latter  factor  itself  could  be  the
basis for  development  of  AL.  However,  from  the  point  of
view of  Greaves,71 when  the  child  does  not  have  an  early
infection (before  1  year  of  life)  the  response  provoked  in
the immunological  system  when  an  infection  occurs  later
on would  be  much  more  aggressive  and  trigger  a  second
mutation. This  may  have  as  a  consequence  development
of ALL  (acute  lymphoblastic  leukemia).  Greaves  and  Chan
point that  the  mutation  is  not  necessarily  germinal,  but
that mutations  could  be  spontaneous.  During  the  ﬁrst  year
of life,  it  is  estimated  that  there  are  1.8  ×  1013 pre-B
lymphocytes produced,  which  increases  the  probability  of
producing a  pre-B  cell  with  a  spontaneous  mutation.72 If,
in addition,  between  2  and  4  years  of  age  an  infection
occurs, the  biological  marker  is  created  in  which  ALL
could develop.  This  suggests  the  participation  of  HLA.  If  a
late infection  occurs  (particularly  viral  infections)  in  the
child who  experienced  a  spontaneous  mutation  and,  in
addition, the  HLA  does  not  allow  for  the  attack  against  this
infectious agent  to  be  regulated.56 This  would  generate  an
exaggerated response  against  the  infection  and  provoke  the
second mutation  required  for  the  development  of  ALL.69,70
Therefore,  evaluating  the  HLA  in  the  child  with  Down’s  syn-
drome would  have  great  importance.  The  non-susceptible
population (without  Down’s  syndrome  as  a  population
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ontrol)  has  the  same  probability  of  having  the  risk  allele
or protection)  of  HLA  as  a  child  who  does  develop  ALL  or
nother type  of  AL  because  these  controls  may  not  have
xperienced the  ﬁrst  mutation.  A  mutation  already  exists
n the  child  with  Down’s  syndrome.  Although  trisomy  21  or
he alterations  that  may  arise  in  other  genes  would  not  be
he factors  that  directly  predispose  to  AL,  a  low  capacity
f DNA  repair  exists73 and  there  would  be  a  higher  risk  of
resenting a  spontaneous  mutation  in  pre-B  cells.  Similarly,
f there  is  a  spontaneous  mutation  plus  the  presence  of  the
LA risk  allele  (or  the  absence  of  one  of  protection)  when
n exaggerated  response  to  an  infection  occurs  together
ith an  exposure  to  another  factor  that  has  the  potential
or causing  leukemia,  the  child  could  develop  the  disease.
Chan  and  Greaves71 and  Chan72 proposed  that  the  suscep-
ibility for  ALL  is  more  acquired  than  germinal,  as  offered  by
he Knudson  theory  or  the  Gardner  hypothesis  for  explaining
he cases  of  ALL  that  appeared  in  Sellaﬁeld.  In  this  report,
ardner et  al.  note  that  there  is  a  mutation  that  the  par-
nts transmit  to  their  progeny,74 even  though  this  proposal
as been  widely  criticized.75--77 Within  that  acquired  suscep-
ibility, one  could  also  include  dietary  causes  (deﬁciency)
nd even  stressors.59 These  two  last  factors  warrant  fur-
her investigation.  Considering  the  limitation  of  establishing
n adequate  causal  relationship,  they  could  cause  a  cer-
ain susceptibility  both  for  carcinogenic  substances  (as  is  the
ase that  some  nutritional  deﬁciencies  are  associated  with
 greater  effect  of  radiation)  as  a  poor  immune  response
gainst cancer  cells.78 These  factors,  however,  act  at  a  spe-
iﬁc time  of  the  child’s  life  and  may  be  considered  that  the
redisposition is  only  momentary.  This  is  of  great  importance
ecause a  child  with  a  high  susceptibility  for  AL,  as  is  the
hild with  Down’s  syndrome,  on  being  exposed  to  a  poten-
ially leukemogenic  factor,  could  develop  AL  if  the  exposure
ccurs at  a  time  in  which  the  susceptibility  to  that  factor
ncreases. Consequently,  for  two  children  with  Down’s  syn-
rome who  are  exposed  to  the  same  risk  factor,  what  can
etermine that  one  develops  AL  and  not  the  other  is  the
ime of  greater  susceptibility.70,79
.3.  Period  of  vulnerability
inally,  one  must  consider  that  this  ‘‘time  of  increased  sus-
eptibility’’  not  only  can  determine  a  normal  or  abnormal
esponse to  an  infection  where  the  B  cells  might  be  more
usceptible to  mutate  or  a  deﬁciency  of  some  particular
utrient or  some  stress  factor.  This  time  could  also  be  a
iologically determined  time.  The  peak  age  of  ALL  (espe-
ially common  ALL  or  CD10  positive)  is  between  2  and  4
ears, whereas  AML  (acute  myeloid  leukemia)  does  not  have
 peak  age  in  those  <15  years  of  age.80 Greaves  notes  that
f a spontaneous  mutation  occurred  during  the  ﬁrst  year  of
ife, it  is  during  this  age  when  a  child  is  more  predisposed  to
evelop a  second  mutation  in  response  to  an  infection.72,81
f  this  hypothesis  is  set  aside  and  it  is  considered  that  dur-
ng the  ﬁrst  3  years  of  life  there  is  a  great  production  of
ells from  the  immune  apparatus,  especially  pre-B  cells82hen  there  is  a high  level  of  proliferation  found,  this  alone
ould increase  the  effect  of  any  carcinogen,  from  an  infec-
ious one  to  a  chemical  exposure.83--85 Accepting  that  during
his period  in  which  the  child  becomes  most  vulnerable  to
60  J.M.  Mejía-Aranguré
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Figure  1  What  is  required  for  an  acute  leukemia  to  be  devel-
oped in  children?  An  inverse  relationship  between  the  degree
of exposure  to  environmental  factors  and  the  degree  of  suscep-
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Figure  2  Model  of  interaction  between  exposure,  suscepti-
bility and  vulnerability.  A  child  requires  being  susceptible  to
leukemia so  that  an  environmental  factor  could  cause  the  devel-
opment of  acute  leukemia.  The  same  occurs  in  an  inverse
fashion. However,  this  interaction  potentiates  when  there  is
a signiﬁcant  degree  of  proliferation  in  hematopoietic  cells
that allows  for  acute  leukemia  to  be  produced.  In  this  model,
it is  called  the  period  of  vulnerability.  In  acute  lymphoblas-
tic leukemia  (ALL)  this  period  of  natural  vulnerability  occurs
between 2  and  6  years  of  age,  a  time  in  which  the  peak  age  of  the
leukemias appears.  When  the  interaction  between  the  exposure
and the  susceptibility  occurs  during  this  period  of  life,  the  risk
of a  child  developing  ALL  increases.  This  scheme  seeks  to  illus-
trate that  if  susceptibility  is  increased  for  a  few  years  in  children
who will  develop  ALL  (illustrated  with  dotted  line),  for  example,
between 2  and  6  years  of  age,  they  would  require  little  exposure
(thin arrow)  to  develop  leukemia.  On  the  other  hand,  during
the period  when  susceptibility  is  low,  more  exposure  would  be
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oibility: the  more  exposure  a  child  has,  the  less  susceptibility
o develop  leukemia.  The  more  susceptible  the  child,  the  less
xposure required  for  developing  leukemia.  AL,  acute  leukemia.
arcinogens  is  a  biologically  determined  time  where  the  tis-
ue or  organ  affected  is  found  to  be  in  greater  proliferation,
his would  explain  the  peak  ages  in  which  the  different  neo-
lasms occur.49,80,86 However,  this  biological  time  of  greater
ulnerability would  only  explain  cancer  cases  that  appear
uring peak  ages,  whereas  the  momentary  susceptibility
ould explain  the  cases  that  appear  outside  the  peak  age.
or example,  if  an  8-year-old  susceptible  (Down’s  syndrome)
hild suffers  an  infection  by  an  agent  not  well  recognized  by
he HLA  or  causes  an  abnormal  response  or  simply  provokes
 greater  proliferation  of  B  cells,  the  infection  if  caused  by
n oncogenic  virus  could  be  sufﬁcient  to  cause  a  neoplasm  or
ender the  child  vulnerable  for  the  effect  of  another  onco-
enic factor  (X-rays,  electromagnetics,  etc.),  ﬁnally  leading
o the  development  of  AL  (Figs.  1  and  2).  Summing  up,
t can  be  said  that  the  factors  related  with  the  causality
f AL  are  three:  exposure,  susceptibility  and  time.  These
hree phenomena  maintain  a  narrow  equilibrium.  There-
ore, in  a  society  where  the  susceptible  population  increases
long with  the  exposure  factors,  the  frequency  of  AL  will
ncrease. Only  if  it  is  better  understood  how  a  child  develops
eukemia, the  disease  may  be  prevented.87
. General model
o  identify  the  origin  of  different  biological  processes  in  dis-
ase is  difﬁcult  due  to  the  complex  interaction  among  the
ariables involved  in  disease  onset.  This  holds  true  for  ALL  in
hildren. In  recent  years,  it  has  been  possible  to  identify  dif-
erent aspects  concerning  the  molecular  biology  of  disease,
ith several  genetic  susceptibility  factors  having  been  iden-
iﬁed for  childhood  leukemia.  However,  less  successful  has
een  the  search  for  causal  environmental  factors.There  does  not  seem  to  be  a  clear  answer  as  to  why  chil-
ren become  sick  with  ALL.  At  present,  it  is  accepted  that
LL is  the  result  of  the  interaction  between  susceptibility
o the  disease  and  exposure  to  cancer-causing  agents  in  the
s
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iecessary (thick  arrow).  B,  birth.
nvironment.  Nevertheless,  distinct  attempts  using  molecu-
ar epidemiology  have  failed  to  demonstrate  an  interaction
etween susceptibility  factors  and  such  environmental  fac-
ors. Thus,  the  solution  does  not  seem  to  be  so  simple  a
elationship. I  propose  a model  in  which  I  integrate  current
heories concerning  childhood  ALL  and,  in  addition,  pro-
ose a  new  approach  by  which  to  study  the  causes  of  this
nﬁrmity.
In this  model  I  propose  that  susceptibility  to  childhood
LL should  not  be  viewed  as  being  determined  solely  by  a
enetic factor  or  by  whatever  other  individual  factor.  Rather,
usceptibility should  be  understood  as  a  phenomenon  com-
osed  of  different  variables.  It  is  these  variables,  working
n conjunction,  perhaps  synergistically,  which  result  in  the
henomenon of  susceptibility.  That  is,  susceptibility  to
hildhood ALL  should  not  be  seen  as  only  one  individ-
al characteristic,  rather,  a cluster  of  interacting  variables
etermines whether  a  child  becomes  susceptible  to  the
isease.
More speciﬁcally,  I  propose  the  existence  of  a  gradient
f susceptibility  in  which  an  individual  not  only  is,  or  is  not,
usceptible, but  also  may  be  found  within  a gradient,  with
he individual  being  more  or  less  susceptible.  (Note  that  the
odel does  not  exclude  the  existence  of  non-susceptible
ndividuals). Similarly,  such  a  susceptibility  gradient  may  be
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composed  of  two  principal  components:  1)  susceptibility  to
the disease,  as  is  the  case  for  some  genetic  rearrangements,
such as  MLL/AF4,  ETV6/RUNX1,  etc.,  and  2)  susceptibility
to the  carcinogenic  effect  of  environmental  factors,  as  is
the case  for  the  genes  related  to  methylation,  which  are
involved in  the  development  of  ALL.
Similarly,  exposure  to  environmental  factors  should  not
be understood  only  as  either  being  exposed,  or  not  exposed,
to determined  carcinogenic  factor(s).  Such  exposure  should
also be  regarded  as  a  phenomenon  that  implies  a  gra-
dient, ranging  from  no  exposure,  to  little  exposure,  to
high exposure  to  carcinogenic  substances.  This  goes  beyond
considering only  the  exposure  dose  and  implies  instead  expo-
sure to  several  environmental  factors  or  exposure  to  many
carcinogenic factors.  Exposures(s)  could  occur  to  the  mother
before conception  or  to  the  child  during  gestation  and/or
in the  postnatal  period  before  development  of  the  disease.
Consequently, according  to  this  model,  if  there  were  expo-
sure to  many  environmental  carcinogens  during  one  or  more
of these  stages,  the  probability  of  the  child  developing  ALL
would be  increased.
Taking into  account  both  phenomena  (susceptibility  and
exposure), we  may  then  deduce  that  ALL  is  the  result  of
the interaction  between  a  gradient  of  susceptibility  and
a gradient  of  exposure  to  carcinogenic  environmental  fac-
tors. Thus,  if  an  individual  has  high  susceptibility  to  the
disease, few  environmental  factors,  or  little  exposure  to
such environmental  factors,  will  be  needed  to  develop  ALL.
Conversely, for  the  phenomenon  of  exposure,  the  greater
the exposure  that  a  child  has  to  carcinogenic  environmen-
tal factors,  the  less  susceptibility  to  the  disease  would  be
needed to  develop  the  illness  (Fig.  1).
In  addition  to  the  foregoing,  we  consider  it  necessary  to
take into  account  another  very  important  variable  that  has
been  considered  in  all  the  theories  on  ALL,  especially  in  that
for early  pre-B  lymphoblastic  leukemia:  the  age  of  the  child
at the  onset  of  the  disease.  In  a  manner  analogous  to  that
for other  childhood  cancers,  it  has  been  observed  that  the
age of  the  child  at  onset  of  the  cancer  not  only  is  a  reﬂection
of the  degree  of  susceptibility  to  the  disease  (i.e.,  the  most
susceptible being  the  children  in  whom  the  cancer  appears
earliest, such  as  is  the  case  for  bilateral  retinoblastoma  or
bilateral Wilms’  tumor,  the  age  at  onset  of  which  is  ear-
lier than  that  of  the  unilateral  forms),  but  also  is  a  third
phenomenon in  the  development  of  disease.  We  call  this
phenomenon the  ‘‘vulnerability  period’’  of  a  tissue  and  we
deﬁne it  as  the  stage  of  the  greatest  cellular  proliferation
of that  tissue,  which  can  be  determined  biologically  either
by developmental  age  or  by  provocation  by  external  agents,
e.g., infections.
This apparent  period  of  vulnerability  can  be  seen  in  other
tumors; for  example,  for  retinoblastoma.  This  vulnerable
period appears  primarily  during  the  ﬁrst  three  years  of  life,
the stage  of  maturation  of  the  retina;  in  osteosarcoma,  the
age at  onset  of  the  tumor  is  highly  related  with  the  growth
spurt of  the  adolescent,  in  which  there  is  a  great  cellular
proliferation of  bone  tissue.  Thus,  with  the  incorporation  of
this vulnerable  period  as  a  third  phenomenon  in  our  model,
the age  at  onset  of  the  ALL  reﬂects  the  degree  of  vulner-
ability of  the  tissues.  Therefore,  we  conclude  that  ALL  is
the result  of  the  interactions  among  the  three  phenomena
described above:  the  gradient  of  susceptibility,  the  gradient
161
f  exposure  to  carcinogenic  environmental  factors,  and  the
issue vulnerability  period  (Fig.  2).
This  model  will  permit  investigators  to  redesign  studies
or identifying  environmental  risk  factors  related  to  ALL,  as
ell as  the  studies  that  attempt  to  evaluate  the  importance
f some  characteristic  related  to  susceptibility  to  ALL.  In
ddition, the  model  encompasses  the  existing  theories  of
ome types  of  ALL,  but  above  all,  it  permits  the  integration
f knowledge  about  ALL  to  date,  from  the  environmental
spects to  the  molecular  processes  involved  in  the  onset  of
he disease.  It  is  probable  that  this  model  may  be  modiﬁed
or application  to  the  majority  of  childhood  cancers  and,
herefore, could  change  the  manner  in  which  investigators
earch for  the  cause  of  these  inﬁrmities.
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